ABBV · بایگانی پژوهش ماهانه

ABBV May 2026 · hold

AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.